Skip to main content
XCUR
NASDAQ Life Sciences

Exicure HiTron Reclaims 623K Shares, Lifting Stake to 34.9% Amid Financial Distress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.665
Mkt Cap
$10.613M
52W Low
$1.43
52W High
$9.5
52W Position info
16% above low
Off High info
82% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

XCUR sits 16% above its 52-week low of $1.43.

Summary

Exicure HiTron Inc. reacquired 623,277 shares of Exicure, Inc., raising its stake to 34.87% amid the biotech's ongoing financial struggles.


Key Events · Ownership and Investor Activity · XCUR

  • Major Shareholder Reclaims 623K Shares

    Exicure HiTron Inc. reacquired 623,277 shares from five prior transferees via amended agreements, reducing total transferred shares from 1,246,552 to 618,108 and retaining KRW 4,160,554,000 in proceeds.

  • Ownership Stake Rises to 34.87%

    Following the reacquisition, HiTron beneficially owns 2,222,224 shares, representing 34.87% of Exicure's 6,373,937 outstanding shares, up from a previously reported lower stake.

  • Two Purchasers Retain 487K Shares

    Lee So-jung and Kim Jun-seo did not participate in the amended agreements and continue to hold 487,834 shares; HiTron may pursue recovery under pledge arrangements, with no assurance of outcome.

  • Backdrop of Severe Financial Distress

    Exicure reported a going concern warning and dwindling cash in its May 2026 10-Q, making HiTron's consolidation of control a potentially pivotal factor in future financing or strategic decisions.


Analysis · XCUR · Life Sciences

Exicure HiTron Inc., the largest shareholder of Exicure, Inc., has reacquired 623,277 shares from five prior transferees through amended agreements, increasing its beneficial ownership to 2,222,224 shares or 34.87% of outstanding common stock. The reacquisition consolidates control at a time when Exicure faces severe financial distress, including a going concern warning and dwindling cash reserves. The move signals HiTron's commitment to maintaining influence over the company's strategic direction, potentially impacting future financing or partnership decisions. Two other purchasers did not return shares, and HiTron may seek recovery, adding uncertainty.

At the time of this filing, XCUR was trading at $1.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.6M. The 52-week trading range was $1.43 to $9.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XCUR - Latest Insights

XCUR
Jul 17, 2026, 1:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
XCUR
Jun 30, 2026, 3:03 PM EDT
Source: Wiseek News
Importance Score:
7
XCUR
Jun 30, 2026, 2:55 PM EDT
Filing Type: 8-K
Importance Score:
7
XCUR
May 29, 2026, 2:09 PM EDT
Filing Type: 10-Q
Importance Score:
9
XCUR
Apr 22, 2026, 7:57 PM EDT
Source: Reuters
Importance Score:
8
XCUR
Apr 10, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
XCUR
Apr 02, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
XCUR
Mar 27, 2026, 4:43 PM EDT
Source: Wiseek News
Importance Score:
7
XCUR
Mar 27, 2026, 4:40 PM EDT
Filing Type: 8-K
Importance Score:
7
XCUR
Mar 25, 2026, 4:42 PM EDT
Filing Type: 10-K
Importance Score:
9